Stockwinners Market Radar for February 01, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:19 EST Cathie Wood's ARK Investment bought 62.4K shares of Pinterest today

20:17 EST Cathie Wood's ARK Investment bought 24.8K shares of Tesla today

19:50 EST Genprex trading halted, news pending

19:50 EST Biosig Technologies trading halted, news pending

17:53 EST Amazon says it made 'meaningful progress' on delivery in U.S. in Q4 - Says improvements in delivery speed have led to increases in orders by Prime members. Says AWS approach to "democratizing" AI resonating well with customers.

17:38 EST Hologic's Genius Digital Diagnostics System cleared by FDA - Hologic's new Genius Digital Diagnostics System with the Genius Cervical AI algorithm has received clearance from the FDA, making it the first and only FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. Screenings for cervical cancer include a Pap test, where a sample is generally collected at an OB-GYN office, and the cervical cells are sent to a lab where they are transferred to a glass slide. With the Genius Digital Diagnostics System, the glass slides are digitally imaged and an artificial intelligence algorithm is applied to pinpoint the cells that cytologists and pathologists should review. The new process and technology demonstrated an overall improvement in sensitivity without a corresponding decrease in specificity. There was a 28% reduction in false negatives of high-grade squamous intraepithelial and more severe lesions compared to microscopic review. The Genius Digital Diagnostics System is already commercially available in Europe, Australia and New Zealand. Commercial availability in the U.S. is expected in early 2024.

17:34 EST Apple CFO says Q2 total revenue and iPhone revenue to be similar to year-ago - CFO Luca Maestri states: "The color we are providing today assumes that the macroeconomic outlook doesn't worsen from what we are projecting today for the current quarter. And we expect foreign exchange to be a revenue headwind of about 2 percentage points on a year-over-year basis. As a reminder, in the December quarter a year ago, we faced significant supply constraints on the iPhone 14 Pro and 14 Pro Max due to COVID-19 factory shutdowns. And in the March quarter a year ago, we were able to replenish channel inventory and fulfill significant pent-up demand from the constraints. We estimate that this impact added close to $5B to the March quarter's total revenue last year. When we remove this impact from last year's revenue, we expect both our March quarter total company revenue and iPhone revenue to be similar to a year ago. For our Services business, we expect a similar double-digit growth rate to what we reported in the December quarter. We expect gross margin to be between 46% and 47%. We expect OpEx to be between $14.3B and $14.5B. We expect OI&E to be around $50 million, excluding any potential impact from the mark-to-market of minority investments and our tax rate to be around 16%." Comments taken from Q1 earnings conference call.

17:15 EST Meta Platforms sees FY24 capital expenditures $30B-$37B - Sees FY24 tax rate in mid-teens percentage range. Says expects to incur larger operating costs in FY24. Says AI is growing area of investment in 2024, Says Reality Labs is the other long-term initiative the company invests heavily in. Says expects Reality Labs operating losses to increase meaningfully. Says has big recruiting backlog from last year.

17:14 EST Apple CEO says to make announcement on AI product later this year - CEO Tim Cook stated: "As we look ahead, we will continue to invest in technologies that will shape the future. That includes artificial intelligence where we continue to spend a tremendous amount of time and effort, and we're excited to share the details of our ongoing work in that space later this year." Comments taken from Q1 earnings conference call.

17:05 EST Southside Bancshares increases quarterly dividend 2.9% to 36c per share - The board of directors of Southside Bancshares approved a 2.9% increase to the regular quarterly cash dividend of 1c, to 36c per common share and declared a regular quarterly cash dividend of 36c per common share. The cash dividend of 36c is scheduled for payment on February 29, to common stock shareholders of record on February 15.

16:58 EST Meta Platforms says will discontinue reporting Facebook MAUs, DAUs - Says company will discontinue reporting Facebook monthly active users, or MAUs, and daily active users, or DAUs. Says working toward the launch of Llama 3. Says continues to leverage Ai across ad suite.

16:35 EST Apple reports Q1 Greater China revenue $20.82B vs. $23.91B last year

16:34 EST Apple shares drop 2% to $183.96 following Q1 beat

16:33 EST Apple Q1 Wearables, Home, Accessories sales $11.95B vs. $13.48B last year

16:33 EST Apple reports Q1 iPad revenue $7.02B. vs. $9.4B last year

16:32 EST Apple reports Q1 iPhone revenue $69.7B vs. $65.78B last year

16:31 EST Apple declares quarterly dividend of 24c per share - Apple's board has declared a cash dividend of 24s per share of the company's common stock. The dividend is payable on February 15, to shareholders of record as of the close of business on February 12.

16:27 EST Trian Group files proxy statement in connection with Disney board nominations - The Trian Group, which owns $3B of common stock in Disney, filed its definitive proxy statement with the Securities and Exchange Commission in connection with its nomination of Nelson Peltz and James Rasulo for election to the Disney board of directors at the company's 2024 annual meeting of Shareholders and released a letter to its fellow Disney shareholders. The full text of the letter is below: "...Despite Disney's enviable and unique position in media and entertainment, its stock price is half what it was less than three years ago and Disney shareholders - like you and us - have collectively lost nearly $200 billion of our investment in that time.2 Disney's recent creative efforts have disappointed its once-loyal customer base and have caused losses for shareholders. Disney was forced to cut its dividend and only recently restored it - meanwhile shareholders missed out on more than $12 billion in expected distributions between 2020 and 2023. Disney's stock is down over the last one, three and five years. In fact, over those time periods, Disney's total shareholder return ("TSR") has significantly underperformed the stocks of other media and entertainment companies, despite Disney's superior assets, capabilities and businesses. Disney's TSR has underperformed the S&P 500 by a wide margin over each of those time periods, too.5 One year ago, three years ago, five years ago or ten years ago, you would have been far better served investing in an index fund like the S&P 500, or in a basket of Disney's self-selected peers, than in Disney itself.6 Instead, you, like us, have been caught in the Disney mousetrap... As a result of these and other issues, and despite spending $200 billion since 2018 on assets and acquisitions (such as the purchase of 21st Century Fox), Disney's financial performance has suffered. Operating income, free cash flow and earnings per share have declined by 18%, 50% and 85%, respectively, since 2018.14 In our view, Disney's strategic missteps and declining financial performance can be laid at the feet of its Board, which we believe lacks focus, alignment and accountability... We do not believe the current Board can solve Disney's problems. To Restore the Magic, we need new perspectives, fresh thinking and tangible goals. We certainly do not expect this same Board that has sat idle, watching Disney's decline, to suddenly change and have the drive to fix Disney. So, to ensure a better future for this great company, we, its owners, must act! We are therefore asking you to elect two new, independent directors - Nelson Peltz and Jay Rasulo - to Disney's Board of Directors... If elected, Nelson Peltz and Jay Rasulo will seek to work diligently and collaboratively with the other Disney directors and management to: Initiate a Board-led review of the Company's creative processes and structure so that Disney can once again claim its #1 position at the box office while consistently delivering industry-leading content and Disney hallmarks; Insist that management finally develop and implement an executable plan for the streaming business in order to achieve Netflix-like levels of profitability; Have the leadership team commit to a detailed plan that includes a reasonable payback period and return profile for all future investments in the direct-to-consumer ESPN business; Press management to disclose the expected returns on the $60 billion of announced investments in the Parks and Experiences business; Align pay and performance for the Company's senior leaders by tying compensation to clear, measurable and ambitious goals; and Finally execute a successful CEO succession process, while cultivating a deep bench of capable, next-generation leaders. We encourage you to vote "FOR" Nelson Peltz and Jay Rasulo using the instructions on the enclosed BLUE proxy card to enable them to pursue this ambitious agenda.To make room for Nelson Peltz and Jay Rasulo on the Board, you also need to "WITHHOLD" your vote on two of the Board's current directors. We are strongly recommending shareholders "WITHHOLD" on incumbent directors Michael Froman and Maria Elena Lagomasino."

16:21 EST Deckers Outdoor jumps 5% to $815 after Q3 results beat estimates, CEO change

16:20 EST Beazer Homes: Title insurer provider experienced cyber incident in December - The company said "At the end of December, one of our title insurer providers experienced a cybersecurity incident, which delayed a number of closings in the quarter. Although the delayed closings led to slightly lower revenue and earnings in the quarter, I'm pleased to report that these delayed closings were all completed during the first two weeks of January and that the title insurance provider has returned to normal operations."

16:18 EST Clorox jumps 5% to $155.45 after Q2 results beat estimates, FY24 guidance raised

16:16 EST reAlpha names Mike Logozzo as new COO, Michael Frenz as new CFO - reAlpha Tech "announced the following leadership changes: Mike Logozzo has been appointed as the Company's President and Chief Operating Officer; Jorge Aldecoa has been appointed to the new role of Chief Product Officer; and Michael Frenz has been appointed as Chief Financial Officer. The appointments are effective immediately. Mr. Aldecoa and Mr. Frenz will report to Mr. Logozzo, who will report to Giri Devanur, the Company's Chairman and Chief Executive Officer. As President and COO, Mr. Logozzo takes the helm, steering reAlpha through day-to-day operations, strategy, and compliance. Bringing over 25 years of experience in the financial services and operations industry, including more than 15 years at BMW, and a proven capital raising track record, Mr. Logozzo has been with reAlpha since the beginning and played a pivotal role in the company's Nasdaq debut and beyond. In his new role as Chief Product Officer, Mr. Aldecoa brings over 15 years of experience in the residential and commercial real estate industry. Tasked with commercializing reAlpha's AI technologies, his real estate industry knowledge, and successful implementation of a property management platform to facilitate acquisition and management of newly-constructed single-family rental homes at previous positions, will be pivotal for product innovation and business growth. Mr. Aldecoa's leadership will also guide the potential acquisition of future technologies, enriching reAlpha's tech portfolio."

16:14 EST Clorox reports Q2 gross margin up 730 bps to 43.5% from 36.2% a year ago - Gross margin increased 730 basis points to 43.5% from 36.2% in the year-ago quarter, due to the benefits of pricing and cost-savings initiatives, more than offsetting unfavorable foreign exchange rates. Gross margin also reflects the benefit of better cost absorption from strong shipment growth.

16:13 EST Meta Platforms announces $50B increase to share repurchase authorization

16:13 EST Manhattan Associates director Noonan sells 7,481 common shares - In a regulatory filing, Manhattan Associates director Thomas Noonan disclosed the sale of 7,481 common shares of the company on December 12 at a price of $223.111 per share.

16:12 EST Microchip increases quarterly dividend 25.7% y/y to 45c per share - Microchip announced that its Board of Directors declared a quarterly cash dividend on its common stock of 45c per share. The dividend is payable on March 8, 2024, to stockholders of record on February 23, 2024. Microchip initiated quarterly cash dividend payments in the third quarter of fiscal year 2003 and has increased its dividend 80 times since its inception. "Microchip's financial performance in the December 2023 quarter fell short of our guidance, however, cash generation remained strong and we continued to make progress towards our capital return strategy," said Steve Sanghi, Executive Chair. "Today, our Board of Directors approved a year-over-year increase in our dividend of 25.7% to 45.0 cents per share, up from our February 2023 dividend of 35.8 cents per share. This represents 86 consecutive quarters of dividend payments for Microchip and reflects confidence in the cash-generating capability of our business, as well as our ongoing commitment to returning capital to our stockholders. Despite the current market dynamics, we remain committed to return 100% of our adjusted free cash flow to shareholders by the March 2025 quarter."

16:10 EST Meta Platforms reports Facebook DAUs 2.11B on average for December 2023 - Facebook MAUs were 3.07 billion as of December 31, 2023, an increase of 3% year-over-year. DAUs were 2.11 billion on average for December 2023, an increase of 6% year-over-year.

16:09 EST Cantaloupe completes acquisition of Cheq Lifestyle Technology - The company stated: "Cantaloupe announced the successful completion of its acquisition of Cheq Lifestyle Technology, Inc.. This strategic investment positions Cantaloupe for expansion into the large and rapidly growing sports, entertainment, and restaurant sectors with a comprehensive suite of self-service solutions. By leveraging mobile ordering, socially connected payments, real-time reporting, and remote support, CHEQ empowers customers to streamline venue operations, increase efficiency, and boost revenue."

16:07 EST Meta Platforms initiates quarterly dividend of 50c per share - Meta's board of directors declared a cash dividend of 50c per share of our outstanding common stock including both Class A common stock and Class B common stock, payable on March 26, 2024 to stockholders of record as of the close of business on February 22, 2024. "We intend to pay a cash dividend on a quarterly basis going forward, subject to market conditions and approval by our board of directors."

16:06 EST Amazon up 4% after Q4 earnings beat - Amazon shares are up $6.58, or 4%, to $165.86 in after-hours trading.

16:04 EST Nurix Therapeutics announces publication in Science - Nurix Therapeutics announced the publication of a manuscript in the journal Science titled: "Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127" that elucidates a previously unappreciated oncogenic scaffold function of BTK responsible for clinical resistance to enzymatic inhibitors and shows that NX-2127, a targeted protein degrader with differentiated activity against BTK and IKZF1/3, can overcome this resistance across a broad range of acquired mutations. The article describes studies designed to investigate and characterize acquired BTK mutations that confer resistance to BTK inhibitors commonly used in the treatment of B-cell malignancies. The research identified a new class of kinase impaired mutants that render BTK enzymatically inactive and revealed that these mutations create novel protein-protein interactions that can propagate biochemical signaling through a process known as scaffolding, a nonenzymatic function of the BTK protein that sustains B-cell receptor, or BCR, signaling and promotes the growth of malignant B-cells. Importantly, the authors report data demonstrating efficient proteasomal degradation of BTK in the blood of all NX-2127-treated patients with chronic lymphocytic leukemia, or CLL, resulting in reduction of BTK enzymatic activity and suppression of BCR signaling regardless of mutational status. The work was carried out by Nurix in collaboration with scientists and clinicians at several prominent cancer research centers, including Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center.

16:00 EST Montrose Environmental acquires Epic Environmental - Montrose Environmental "announced the acquisition of Epic Environmental Pty Ltd, a leading environmental consultancy in Australia. Epic Environmental's senior leadership team, including founders Mark Breitfuss and Brad May, will join Montrose's Consulting and Engineering division, which reports into the Company's Remediation and Reuse segment. Terms of the transaction were not disclosed. Headquartered in Brisbane, with offices in Sydney, Mudgee, Adelaide and Darwin, Epic Environmental is an environmental science and engineering consultancy, serving clients across Australia. Working across diverse industries and sectors, Epic Environmental's clients today include many of Australia's top industrial, resources and energy services companies."

15:32 EST Amazon announces AI-powered shopping assistant Rufus - Amazon announced Rufus, a new generative AI-powered conversational shopping experience. "Rufus is an expert shopping assistant trained on Amazon's product catalog and information from across the web to answer customer questions on shopping needs, products, and comparisons, make recommendations based on this context, and facilitate product discovery in the same Amazon shopping experience customers use regularly," the company said. "Launching today in beta to a small subset of customers in Amazon's mobile app, Rufus will progressively roll out to additional U.S. customers in the coming weeks." Reference Link

14:57 EST CSX reaches paid sick leave agreements with four unions - CSX announced it has reached agreements with four additional groups of railroad workers to provide paid sick leave benefits. The unions include SMART-TD Conductors/Trainmen, SMART-TD Yardmasters, International Brotherhood of Boilermakers, and Carrolton Road-Transportation Communications Union-represented Engineers/Yardmen/Maintenance of Way employees. These agreements extend coverage to more than 600 employees, the company noted.

14:52 EST Express trading halted, volatility trading pause

14:41 EST MoSys trading halted, volatility trading pause

14:11 EST Adtalem Global Education trading resumes

14:07 EST FTC requires Blackbaud to delete unnecessary data in settlement - Blackbaud will be required to delete personal data that it doesn't need to retain as part of a settlement with the Federal Trade Commission over charges that the company's "lax security allowed a hacker to breach the company's network and access the personal data of millions of consumers including Social Security and bank account numbers," the agency said in a statement. In addition to requiring Blackbaud to delete data that it no longer needs to provide products or services to its customers, the proposed order will prohibit the company from misrepresenting its data security and data retention policies. The proposed order also will require Blackbaud to develop an information security program that would address the issues highlighted by the FTC's complaint. Reference Link

13:53 EST Adtalem says short report 'inexcusably and unacceptably' misrepresents business - Adtalem Global Education responded to claims in a report released on January 30 from Safkhet Capital. "The report contains numerous factual errors, demonstrates a poor understanding of our industry as well as rudimentary transaction accounting, and is a reckless attempt to defame the nation's largest healthcare educator," said Adtalem President and CEO Steve Beard. "Safkhet Capital's inability to accurately state even the most basic facts undermines the credibility of the report and its purported premise. By way of example, the chairperson of Adtalem's Board of Directors is Michael Malafronte (2022 - present), not former Chairperson Lisa Wardell, a fact plainly visible on Adtalem's website. Additionally, erroneous figures are referenced for enrollment and graduation rates when accurate data is freely available from publicly accessible, U.S. government sources as well as from Adtalem's own disclosures. The Safkhet Capital report also stated, "for-profits produce disastrously substandard results with most students unable to graduate, and even those who do face high levels of underemployment and higher levels of indebtedness." We do not know where Safkhet Capital found data to support these assertions and, as it pertains to Adtalem, these claims are categorically false. Adtalem is proud to produce more nursing and Doctor of Veterinary Medicine (DVM) graduates than any institution in the U.S., award more medical and research doctoral degrees to African Americans than any other U.S. institution, and to have achieved 98% first-time residency attainment for graduates of our medical schools last year. Errors and gross misrepresentations of the nature described above are too numerous in the Safkhet Capital report to warrant a complete recounting, but they illustrate the flimsiness of the research. As for many of the claims made by Safkhet Capital - they are misleading, incomplete, and factually inaccurate. Because of Adtalem's systemically important role in delivering practice-ready clinicians to the U.S. healthcare system, we feel compelled to correct some of the more egregious errors in the repor... While presenting itself as an advocacy effort in service of student borrowers and taxpayers, in fact, the Safkhet Capital report amounts to nothing more than a thinly veiled and deceptively constructed "short and distort" scheme designed to extract a quick return at the expense of Adtalem's students, faculty, employees and shareholders."

13:44 EST Marathon Digital to replace Hut8 as operator of two Bitcoin mining sites - Marathon Digital (MARA) has entered into an agreement with affiliates of Hut8 Mining Corp. (HUT) to remove Hut8 as the operator of two Bitcoin mining sites recently acquired by Marathon in Granbury, Texas and Kearney, Nebraska. Marathon intends to replace Hut8 as the operator of these sites by April 30. "On January 16, 2024, Marathon closed its previously announced acquisition of two Bitcoin mining sites, totaling 390 megawatts of operational capacity. While Marathon assumed ownership of both sites, Hut8 continued to function as the operator. On January 30, 2024, subsidiaries of Marathon and Hut8 entered into an agreement to terminate Hut8 as the operator of these sites and transition the operational responsibilities to Marathon. By removing Hut8 as the third-party operator and assuming direct operational control of both sites, Marathon expects to reduce its operating fees, thereby improving its cost to produce bitcoin, to more effectively participate in energy hedging and other energy management services, and to streamline the implementation of its proprietary technology to improve operational efficiency. The transition is expected to be completed by April 30, 2024, at which point, Marathon will be both the owner and operator of 390 megawatts of capacity in Texas and Nebraska," Marathon stated.

13:29 EST CCSC Technology International Hldngs Ltd trading halted, volatility trading pause

13:26 EST Roadzen Inc trading halted, volatility trading pause

12:39 EST Truist turns positive after report on Insurance unit sale - Shares of Truist Financial moved into positive territory after Insurance Insider reported Stone Point and Clayton Dubilier & Rice are near a deal to acquire Truist Insurance for $15B and that an announcement could be made in the coming days.

12:27 EST Solowin Holdings Ltd trading halted, volatility trading pause

12:00 EST Metropolitan Bank falls -12.3% - Metropolitan Bank is down -12.3%, or -$5.95 to $42.54.

12:00 EST Thermon Group falls -17.1% - Thermon Group is down -17.1%, or -$5.61 to $27.18.

12:00 EST UGI Corporation rises 12.4% - UGI Corporation is up 12.4%, or $2.74 to $24.88.

11:52 EST P&G says Turkey facility evacuated for 'urgent security situation' - A gunman raided a Procter & Gamble factory in Turkey and took seven hostages in protest over the war in Gaza, according to media reports. Procter & Gamble said in an emailed statement to Bloomberg: "The safety of P&G people and our partners is our top priority. Earlier today, we evacuated our Gebze facility and are working with local authorities to resolve an urgent security situation."

11:34 EST Subaru reports January U.S. sales up 0.8% to 44,510 vehicles - Subaru of America reported 44,510 vehicle sales for January, a 0.8 % increase compared with January 2023. "January also marked the 18th consecutive month of month-over-month sales increases," the automaker stated.

11:33 EST Beacon announces acquisition of Roofers Supply of Greenville - Beacon announced that it has completed the acquisition of Roofers Supply of Greenville, headquartered in Greenville, SC with two additional branches located in Charlotte, NC and Raleigh, NC. "Beacon completed nine acquisitions in 2023. This is the first acquisition announced in 2024 as the company continues to drive above market growth and takes steps to realize its goal of being the top commercial roofing distributor in North America. The company exceeded its Ambition 2025 revenue and shareholder return targets for 2023 and continues to advance on achieving its full Ambition 2025 plan," the company stated.

11:04 EST GT Biopharma announces 1-for-30 reverse stock split - GT Biopharma will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "GTBP" and will begin trading on a post-split basis at the market open on February 5, 2024. The CUSIP number for the common stock following the reverse stock split will be 36254L 308. The reverse stock split is part of the Company's plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share for continued listing on The Nasdaq Capital Market. The reverse stock split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on December 18, 2023, which authorized the Company to effect the reverse stock split at the discretion of the Company's Board of Directors within certain parameters approved by stockholders. The Company's Board subsequently approved the final reverse split ratio of 1-for-30.

11:02 EST International Bancshares raises quarterly cash dividend 4.76% to 66c per share - International Bancshares announced that on Jan. 31, 2024, IBC's Board of Directors approved the declaration of a 66c per share cash dividend for shareholders of record of Common Stock, $1.00 par value, as of the close of business on Feb. 15, 2024, payable on Feb. 28, 2024. This dividend represents a 4.76% or 3c per share increase above IBC's previous dividend paid on Aug. 25, 2023.

10:39 EST Bear Cave says B. Riley 'diminishing credibility' not fully recognized by market - In a recently published report titled "Problems at a Billion Dollar Mess," The Bear Cave says that it has investigated "a complicated web that spans an alleged Ponzi scheme, hundreds of millions in suspect transactions, and over a billion dollars of publicly traded market capitalization. From crypto to data centers, to fake stock transactions, to a guilty plea, and now numerous allegations of wrongful conduct, this is one of the most confusing and bizarre situations The Bear Cave has seen." "B. Riley Financial (RILY) is a Los Angeles-based investment bank and financial services company that is invested in a variety of public and private companies including crypto data center platform Applied Digital (APLD). Despite heavy criticism from a collection of prominent activist short-sellers including Marc Cohodes, Wolfpack Research, The Friendly Bear, and Aurelius Value, The Bear Cave believes B. Riley's diminishing credibility is not being fully recognized by the market," The Bear Cave's Edwin Dorsey says. "Problems at B. Riley largely stem from B. Riley's ties to Brian Kahn, an alleged co-conspirator in a large fraud at Prophecy Asset Management." Reference Link

10:23 EST Bit Origin Ltd trading resumes

10:16 EST Blue Bird announces $60M stock repurchase program - Blue Bird announced that its board authorized the company to repurchase up to $60M in the aggregate of its outstanding common stock during the next 24 months. "We are proud of Blue Bird's continued strong performance and are excited to leverage our strong free cash flow generation again to return capital to our shareholders through this new stock repurchase program," said Blue Bird CEO Phil Horlock. "This initiative reflects management's confidence in the health of our business, our long-term growth prospects, and our overall commitment to continually enhancing shareholder value."

10:06 EST Jin Medical International Ltd trading resumes

10:01 EST Silo Pharma preparing pre-IND application for lead drug program SPC-15 - Silo Pharma announced updates for its strategic 2024 focus for its clinical pipeline. The company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology. A dose-ranging non GLP study of SPC-15 is in progress, with a final validation report expected in the first half of 2024. Silo's next prioritized program is SP-26, an innovative non-opioid chronic pain solution, developed as an injectable and dissolvable time-release ketamine-loaded implant for fibromyalgia, utilizing the subcutaneous injection method. As a self-administered treatment, SP-26 holds the potential to be the first at-home ketamine treatment approved for chronic pain management. Silo's collaboration with Columbia University has also produced SPC-14, a nascent Alzheimer's disease therapeutic. With initial positive results from animal studies and more data expected in 2024, Silo believes SPC-14 represents an encouraging development in Alzheimer's disease research. Silo plans to utilize the FDA's streamlined 505(b)(2) pathway for drug approval. This approach, allowing the inclusion of external safety and efficacy data in INDs, is expected to expedite the approval process and can reduce development costs significantly.

10:00 EST Altus Power rises 10.2% - Altus Power is up 10.2%, or 55c to $5.94.

10:00 EST Corteva rises 15.9% - Corteva is up 15.9%, or $7.23 to $52.71.

10:00 EST Conmed falls -12.3% - Conmed is down -12.3%, or -$11.76 to $83.84.

09:48 EST Knightscope says three clients order additional emergency communications tech - Knightscope announces that three of its clients have ordered additional equipment to expand their emergency communications programs. A healthcare provider in Texas, a Colorado county and college have all issued purchase orders for a total of 5 new systems to enhance access to emergency assistive services.

09:47 EST Boot Barn rises 9.5% - Boot Barn is up 9.5%, or $6.79 to $78.53.

09:47 EST Wabash falls -7.3% - Wabash is down -7.3%, or -$1.85 to $23.45.

09:47 EST Conmed falls -12.2% - Conmed is down -12.2%, or -$11.71 to $83.89.

09:41 EST Fibrobiologics Inc. trading resumes

09:39 EST Dippin' Dots enters partnership with Diamond Baseball Holdings - Dippin' Dots announced a new partnership with Diamond Baseball Holdings, an organization that owns and operates Minor League Baseball clubs to further enhance gameday fan experiences. For the 2024 Minor League Baseball season, Dippin' Dots will be available at select DBH-owned Minor League Baseball stadiums across the country. Currently available in 85% of Minor League Baseball stadiums, the new partnership will expand Dippin' Dots' presence and elevate the ballpark experience at four new stadiums, including Peoples Natural Gas Field, home of the Altoona Curve, Excite Ballpark, home of the San Jose Giants, Hadlock Field, home of the Portland Sea Dogs, and Nat Bailey Stadium, home of the Vancouver Canadians.

09:37 EST Honeywell says 'very confident' on pricing execution, margin expansion - Says making good progress implementing AI in operations which should lead to productivity gains.

09:35 EST American Oncology Network Inc trading resumes

09:32 EST Nubia Brand International Corp trading halted, volatility trading pause

09:31 EST Fibrobiologics Inc. trading halted, volatility trading pause

09:30 EST CareMax trading halted, volatility trading pause

09:24 EST Lithium Corp. reports high priority brine targets identified at Fish Lake Valley - Lithium Corporation shares results and interpretations from the 2023 high resolution 2D seismic reflection survey conducted by optionee Morella at the Company's Fish Lake Valley prospect. Morella characterized the results, which showed strong reflective signals from geological layers down to 3 kilometres of depth, as "outstanding". The analysis and interpretation of the 2023 FLV drilling program data produced multiple findings that advance Morella's understanding of lithium occurrences at the site. The newly identified half-graben basin sediments, as well as structures identified and interpreted by Morella, generated high priority brine targets for drill testing, with a key drillhole already proposed to depth of 1,150 metres to test the highest priority target zone in the hanging wall of the newly identified major rift border fault. Fish Lake Valley is one of three Nevada lithium prospects owned by Lithium Corp. The geological setting at Fish Lake Valley is highly analogous to the salars of Chile, Bolivia, and Peru, and more importantly to the nearby Clayton Valley, where Albemarle operates its long running Silver Peak lithium-brine production facility. Morella Corp. optioned the Fish Lake Valley prospect in 2021.

09:23 EST IGC Pharma announces TGR-63 reduces agitation in 'Alzheimer's Mouse Model' - IGC Pharma announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease. Previously disclosed results demonstrate that TGR-63 may successfully alleviate plaque burden in Alzheimer's cell lines and animal models. Plaques are a key hallmark and therapeutic target of Alzheimer's disease. "While we continue to progress our Phase 2b trial of IGC-AD1 as a treatment for agitation in dementia due to Alzheimer's, we are excited by the preclinical results of TGR-63, in particular the profound impact of the drug on plaques and on reducing anxiety in a transgenic Alzheimer's mouse model. In line with IGC Pharma's artificial intelligence and machine learning, AI/ML, initiatives, we plan to leverage cutting-edge AI/ML tools for studying TGR-63's toxicology and protein interactions. By harnessing the power of AI/ML, we expect to accelerate the journey of TGR-63 from preclinical to patient care. We continue progressing IGC-AD1 and TGR-63 enthusiastically and anticipate clinical milestone updates throughout 2024 from our strengthened AD pipeline," said CEO Ram Mukunda...The mice in the APP/PS1 group that received TGR-63 treatment showed significant improvements in their emotional well-being and anxiety levels compared to the group that didn't receive treatment. A series of tests were used to measure these improvements. ...The results from these multiple tests indicate that TGR-63 treatment helped normalize emotional and behavioral responses in our Alzheimer's mouse model, reinforcing its potential as a promising treatment.

09:21 EST Evaxion Biotech prices 3.75M ADSs at $4.00 in public offering - Evaxion Biotech announced the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS and accompanying warrant. MSD Global Health Innovation Fund, a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, is also participating in this offering. The warrants will have an exercise price of $4.00 per ADS, will be exercisable immediately upon issuance and will expire five years following the date of issuance. Each ADS represents ten ordinary shares of the Company. The closing of the offering is expected to occur on or about February 5, 2024, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be $15 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds of this offering to advance the Company's preclinical and clinical pipeline, and for continuing operating expenses and working capital.

09:18 EST Westhaven Gold receives 650 drill hole permit at Shovelnose property - Westhaven Gold has received its 650 drill hole permit on its 100% owned 17,623-hectare Shovelnose gold property. Shovelnose is located within the prospective Spences Bridge Gold Belt, which borders the Coquihalla Highway 30 kilometres south of Merritt, British Columbia. MYAB Permit: 5-year permit; 650 surface drill sites; Trenching/Bulk sampling; Geophysical surveys; Exploration Access Construction; Approved activities must be conducted as outlined in the Description of Work Program. Priority Target Areas: Additional drilling in and around multiple high grade gold intersections; Following up on previously intersected gold at HydBx-02, Line 6, Lear. Drill test unexplained elevated gold in single isolated core holes. Drill gold anomalies in surface rock samples from outcropping quartz occurrences between Line 6 and MIK. Drilling in vicinity of anomalous pathfinder trends in past drill holes; Drill testing zones of extensive silicification.

09:16 EST Stryve Foods expands distribution footprint - Stryve Foods announces a significant expansion in its distribution network. All three of the Company's retail brands, Stryve, Vacadillos and Kalahari, are gaining momentum in the marketplace. The Company continues to build valuable relationships with retail partners and is excited to share, that its products are now available at Love's Travel Stops, Sierra Trading, Anderson Convenience Market, King's Fuel, Energy North, AMCON Distributing Company, Affiliated Foods, AGNE Distributors, Yesway/Allsups, Gate Petroleum, Dickerson Oil, Circle K Florida, and have also expanded distribution at HEB, AWG, Parker Company, Hot Spot, Lunds & Byerly's. Stryve's CEO, Chris Boever, commented, "I am encouraged by our increasing distribution and improved sales velocities. Our highly differentiated brands deliver significantly more protein than traditional meat snacks. Our products are crafted with high-quality beef and a blend of flavorful spices, free from sugar and no artificial preservatives, nitrates, or other additives, making them perfect snacks for health-conscious and flavor seeking consumers alike. We are making fantastic progress in our transformation; I am highly encouraged by our continued performance and increasingly confident in our future."

09:13 EST Mullen Automotive capitalizes on first-mover advantage in EV vans, trucks - Mullen Automotive announces the Company continues to capitalize on its first-mover advantage in the U.S. market with production and deliveries of its Class 1 and Class 3 commercial EVs. "While many of the OEMs and new EV companies have launched their EVs with significant losses, Mullen is out-of-the-gate with a positive gross profit margin per vehicle. EV growth has slowed in the retail segment but continues to increase across the commercial and fleet segments, where we now have a strong vehicle lineup in the market," said David Michery, CEO and chairman of Mullen Automotive. Mullen began Class 3 vehicle production in August 2023 and first vehicle deliveries in September 2023. Mullen Class 1 production began in November 2023 with first vehicle deliveries in December 2023.

09:12 EST Le Mans Ultimate announces Early Access release plan ahead of February launch - Le Mans Ultimate, the official game of the 24 Hours of Le Mans and FIA World Endurance Championship, will be available to the public in Early Access form on Tuesday 20th February, allowing players to get their hands on the game developed by renowned simulation developer, Studio 397 and Motorsport Games. The title will feature all the cars and circuits from the memorable centenary year in 2023, showcasing the exciting arrival of the revered Hypercars from that season. Cadillac, Ferrari, Glickenhaus, Peugeot, Porsche, Toyota and Vanwall, developed with extensive manufacturer support, all featured in the PC-based game. Players will experience the thrill of piloting iconic cars at spectacular laser-scanned circuits with Sebring, Portimao, Spa-Francorchamps, Monza, Fuji, Bahrain and legendary Circuit de la Sarthe in Le Mans all featured in the meticulous detail that Studio 397 are famed for. The price will be set at EUR 29.99 EUR / GBP 24.99 GBP / $32.99 USD for day one release, allowing those who purchase early to capitalise on a lower price point and gain the ability to provide feedback and steer future content. As the game evolves through Early Access, the improved experience and content offering will be accompanied by incremental price increases for new purchasers.

09:10 EST Rocket Companies appoints Alex Rampell to Board - Rocket Companies has appointed Alex Rampell as an independent director to the company's Board of Directors. Rampell currently serves as General Partner at Andreessen Horowitz, focusing on fintech investments. He cofounded many tech-driven financial companies including Affirm, a business in the 'buy-now-pay-later' space, which went public in early 2021. He also cofounded TrialPay, a transactional advertising and payments company serving digital goods and e-commerce clients, which was acquired by Visa in 2015. Varun Krishna, Rocket Companies CEO, also joined the Board of Directors in December 2023. Rampell also serves on the boards of several Andreessen Horowitz portfolio companies.

09:09 EST Verizon appoints Sharpe as EVP, Chief Communications OfficerAllstate - Verizon Communications (VZ) announced the appointment of Stacy Sharpe as Executive Vice President, EVP, and Chief Communications Officer, effective March 4, 2024. Sharpe brings more than two decades of corporate affairs and communications experience with a decorated career at Allstate. Overseeing Verizon's global communications organization, Sharpe succeeds veteran Communications Chief, Jim Gerace, who served at the company for 37 years and was critical to the formation of Verizon and to the company's launch of every generation of wireless technology to date. Sharpe will join Verizon's executive leadership team and report directly to Chairman and CEO Hans Vestberg. Most recently, Sharpe served as SVP for Corporate Brand at Allstate (ALL).

09:08 EST Celularity sees FY24 net sales of biomaterial product, biobanking $50M-$56M - For the full year 2024, the Company expects combined net sales of its advanced biomaterial product and biobanking businesses to be in the range of $50 million to $56 million, consisting of expected net sales of its advanced biomaterial product business in the range of $45.0 million to $50.0 million and expected net sales of its biobanking business in the range of $5.5 million to $6.0 million. For the full year 2024, the Company expects net sales percentage growth of its advanced biomaterial product business to be in the range of 165% to 194% and net sales percentage growth of its biobanking business to be in the in the single digit range, both compared to full year 2023.

09:08 EST 180 Degree Capital notes average discount of NAV per share to stock price of 22% - 180 Degree Capital noted that the average discount between its estimated daily net asset value per share and its daily closing stock price during January 2024, was approximately 22%. This discount was approximately 26% on January 31, 2024. As previously disclosed in a press release on November 13, 2023, 180 Degree Capital's Board of Directors has set two measurement periods of January 1, 2024 to December 31, 2024, and January 1, 2025 to June 30, 2025, in which it will evaluate the average discount between TURN's estimated daily NAV and its closing stock price pursuant to a Discount Management Program. Should TURN's common stock trade at an average daily discount to NAV of more than 12% during either of these measurement periods, 180 Degree Capital's Board will consider all available options at the end of each measurement period including, but not limited to, a significant expansion of 180 Degree Capital's current stock buyback program of up to $5 million, cash distributions reflecting a return of capital to shareholders, or a tender offer.

09:06 EST RTX's Raytheon awarded $20M contract - Raytheon, an RTX (RTX) business, has been awarded a $20M contract through the Strategic and Spectrum Missions Advanced Resilient Trusted Systems consortium to develop a next-generation multi-chip package for use in ground, maritime and airborne sensors. Under the contract, Raytheon will package state-of-the-art commercial devices from industry partners like AMD (AMD) to create a compact microelectronics package that will convert radio frequency energy to digital information with more bandwidth and higher data rates. The integration will result in new system capabilities designed with higher performance, lower power consumption and reduced weight.

09:05 EST HeartSciences appoints Benjamin Glicksberg to Scientific Advisory Board - Heart Test Laboratories announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board. Glicksberg has served as a lead investigator and inventor of multiple algorithms licensed by HeartSciences from Mount Sinai. Dr. Glicksberg currently serves as the Vice President and Head of Data Science and Machine Learning on the leadership team of Character Biosciences.

09:04 EST Comtech receives $544M U.S. Army contract - Comtech announced it received approval from the U.S. Army Contracting Command to move forward on the company's previously announced $544M Global Field Service Representative, or GFSR, contract. Under this contract, Comtech will provide onsite professional engineering services, as well as supply and support the company's satellite and terrestrial networking communications technologies for the Project Manager Tactical Network for the GFSR support program. This task order was awarded on Comtech's existing contract with the U.S. Army, which leverages the ten-year, $5.1B Global Tactical Communications Systems, or GTACS, II indefinite delivery / indefinite quantity, or IDIQ, contract vehicle. Comtech was initially selected as one of multiple GTACS II IDIQ awardees in 2020. The GTACS II contract is designed to support of the Program Executive Office Command, Control and Communications-Tactical and PM TN. GTACS II provides the rapid acquisition of a wide range of C3T hardware, software, engineering services and logistics support services with an emphasis on tactical satellite communications.

09:04 EST Matterport partners with Arcadus to deliver digital twins to US public sector - Matterport announced a partnership with Arcadus, a leading reseller of digital transformation products and services for the public sector, to offer the Matterport Digital Twin Platform to its customers in the United States. With this agreement, Arcadus will become the first value-added reseller of Matterport's digital twin platform for the public sector, offering the company's three core solutions in Property Marketing, Design & Construction, and Facilities Management. Arcadus will support Matterport with access to various government purchasing vehicles, additional support services, and enabling seamless engagement with public sector agencies, contractors, and integrators. "As organizations continue to embrace the value of Matterport, the public sector remains a significant opportunity for growth," said Jay Remley, Chief Revenue Officer, Matterport. "Our partnership with Arcadus adds more powder to our efforts to drive progress and excellence across the U.S. public sector, empowering federal, state, and local agencies to revolutionize how they assess, manage, and optimize their spaces with our federally compliant digital twin platform."

09:03 EST SLR Investment announces $85M in additional funding to advance SPRINT PNS - SPR Therapeutics announced that it has secured $85M in financing including $25M in Series D-1 insider equity and a $60M debt facility. The equity financing was led by Revelation Partners, SPR's lead investor of the Series D equity financing, and incumbent investors, RC Capital and Mutual Capital Partners. The debt facility is provided by SLR Capital Partners and Armentum Partners served as the Company's financial advisor. The funds will be used to capitalize on commercial momentum, customer demand, and market opportunity to expand SPR sales representation in additional U.S. sales territories. "We thank our financing partners and are pleased to raise additional capital to support and accelerate our already significant growth," said Maria Bennett, President, CEO and Founder of SPR Therapeutics. "We have seen strong adoption of the SPRINT System in the last two years resulting in nearly 200 percent growth of our team, and tremendous year-over-year revenue growth of more than 50 percent from 2022 to 2023."

09:02 EST Oncternal Therapeutics reports inducement award under Nasdaq listing rule - Oncternal Therapeutics announced the approval of an inducement award to one new employee, Damien Bresson, who is joining Oncternal as Senior Director, Preclinical and Translation Science. The award will be made on February 1, 2024 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 4,500 shares of Oncternal common stock. The option will have a 10-year term and an exercise price equal to the closing price of Oncternal's common stock on the date of grant. The option will vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the employee's start date, and the rest vesting in equal monthly installments over three years thereafter. The award was approved by Oncternal's compensation committee, comprised entirely of independent directors, as required by Nasdaq Rule 5635(c)(4), and will be granted as an inducement material to the employee entering into employment with Oncternal in accordance with Nasdaq Rule 5635(c)(4).

08:46 EST LQR House board declares 50% stock dividend - LQR House announces the declaration by its Board of Directors of a 50% stock dividend for distribution to all of the Company's shareholders of record at the close of business on February 12, 2024. The Company's Board of Directors declared the dividend at a follow-up meeting board meeting to discuss a previously proposed cash dividend of up to $1 per share and reflects the Board's commitment to shareholder value and its belief in the Company's prospects.

08:45 EST CSP Inc. wins five-year managed services contract for Florida public college - CSPi Technology Solutions has been awarded a five-year, multi-million dollar contract to provide managed services for a prominent Florida public college, one of the largest and most diverse institutions of higher education in the nation. CSPi Technology Solutions will deliver proactive monitoring, management, and support for the college's critical infrastructure, including network, security, and private cloud services.

08:43 EST Actelis Networks receives order for City of Napa intelligent traffic management - Actelis Networks announced that its hybrid-fiber connectivity solution has been recently deployed at traffic intersections throughout the City of Napa, California. Actelis' local partner, Econolite, ordered and installed the solution, completing an Advanced Traffic Management System, ATMS, upgrade project at some of the busiest intersections in the city. Sitting inside the city's traffic cabinets, the newly installed Actelis hybrid-fiber switches provide fiber-grade connectivity to the intersection, transporting critical traffic related information back to the city's traffic operations center. "We pride ourselves on getting the most out of the network infrastructure that is already available and shielding the network from attacks," said Tuvia Barlev, Chairman and CEO of Actelis. "Our ability to boost the performance of existing copper to fiber quality as well as the capability to extend fiber connectivity within the same network, while utilizing cyber-hardened protocols, makes us unique and helps our customers lower their network infrastructure costs and accelerate project timelines."

08:42 EST Enzo Biochem reports results of annual meeting of shareholders - Enzo Biochem announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals: Proposal One - The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company's Board of Directors to hold office for a term ending as of our Fiscal 2024 annual meeting of shareholders, and until each such director's successor is elected and qualified. Proposal Two - The shareholders did not approve, by a non-binding advisory vote, the compensation of the Company's named Executive Officers. Proposal Three - The shareholders ratified the Company's appointment of EisnerAmper LLP to serve as the Company's independent registered public accounting firm for the Company's fiscal year ending July 31, 2024. The Board of Directors resolved unanimously to appoint Kara Cannon and Patricia Eckert on a permanent basis to the roles of Chief Executive Officer and Chief Financial Officer, respectively, removing the "interim" from their titles.

08:41 EST Eos Energy entered a multiyear agreement with SABIC Specialties - Eos Energy Enterprises entered a multiyear agreement with SABIC Specialties' US business unit, SHPP US LLC, a Saudi Basic Industries Corporation, SABIC, affiliate, to supply conductive composite thermoplastic for the Eos Z3 battery module. Over the past four years, Eos and SABIC worked collaboratively to develop a solution using one of SABIC's new resin materials to replace the titanium used in prior Eos battery iterations. "Over the past six years, we've worked hard to take Eos from a research company to an operating company. Moving from the lab to small-scale production, and now to manufacturing at scale, requires partners who bring a mix of scale and expertise," said Joe Mastrangelo, CEO of Eos. "Our entrepreneurial spirit allows us to find creative ways to drive down cost and improve battery performance. In working closely with SABIC Specialties, we specified an innovative new material that we believe can be produced at scale in the United States."

08:40 EST NetSol Technologies announces major updates to Otoz platform, recent traction - NETSOL Technologies announced major updates on its digital retail and mobility technology platform, Otoz, and the latest traction achieved with two key automotive clients, MINI USA and AutoNation. NETSOL Technologies has officially unveiled Otoz 2.0 after implementing major updates to the digital retail and mobility technology platform. MINI Anywhere Powered by Otoz Doubles Enrollment in Past 12 Months; Achieves 5x Increase in Lead Volume. AutoNation Mobility Launches Micro Lease Marketplace, Leveraging Otoz Back-End Technology.

08:39 EST Bigg Digital Assets announces expansion of product, QLUE user base - BIGG Digital Assets announces further expansion of its product and QLUE user base. Blockchain Intelligence Group has partnered with a State Bureau of Investigations that will be using QLUE to enhance their digital forensic capabilities, which in turn will streamline investigations and resolve cryptocurrency-related cases quickly and affordably. This collaboration underscores the growing need for QLUE, as it enables legal authorities to combat financial crimes involving cryptocurrencies and to ensure the security and integrity of their financial systems. Blockchain Intelligence Group is further pleased to announce it has secured a National Police Agency in an overseas country. This strategic partnership establishes QLUE as a critical instrument to effectively address cryptocurrency-related investigations in the region. This success sets the stage for future opportunities, with Blockchain Intelligence Group ready to provision additional seats as new sales develop and the partnership between the company and the law enforcement agency matures. The combined revenue for these new relationships is approximately CAD$164K.

08:38 EST SeaStar Medical granted Canadian patent with claims covering SCD technology - SeaStar Medical announces the issuance by the Canadian Intellectual Property Office of Canadian Patent No. 2814586. This new patent has broad claims covering the Company's Selective Cytopheretic Device, SCD, technology. Its issuance expands SeaStar Medical's international patent rights and complements existing U.S. patent rights. "A significant opportunity exists to improve treatment of dysregulated hyperinflammatory response that can cause multiorgan damage and even death. The SCD is an innovative and proven approach that selectively targets highly active inflammatory cells to quell the hyperinflammatory response resulting from a range of conditions, and potentially reverse organ injury," said Eric Schlorff, CEO of SeaStar Medical.

08:36 EST Blade Air Mobility appoints Remi Bouysset as CEO, Blade Europe - Blade Air Mobility announced the appointment of Remi Bouysset as CEO of Blade Europe. Blade Europe passengers can now enjoy helipad-side security clearance at Nice International Airport , enabling helicopter fliers to connect directly to their commercial flights at their departing gates, bypassing the general security screening queues at the airport. Bouysset brings to Blade Europe a wealth of experience spanning 30 years in the travel, hospitality, and luxury sectors. Most recently Mr. Bouysset served as the CEO of Blade's helicopter operating partner in France and Monaco, the Monacair Group. Separately, Blade Europe also appointed Benoit Cocheteux, an experienced aviation and logistics executive as Chief Operating Officer, who joins Blade Europe's management team led by Mr. Bouysset.

08:36 EST EpicQuest Education enters sports events and kinesiology markets - EpicQuest Education announced a corporate strategy update as a result of it having recently established two subsidiaries that operate in the sports-related entertainment and the sports, kinesiology and fitness academics fields. The company believes that its 40% owned sports-entertainment subsidiary has the potential to generate substantial revenue from even a single sporting event. As announced on January 18, the company's sports-related entertainment subsidiary entered into an agreement with the Argentine Football Association for the Argentina Men's National Soccer Team to play two exhibition matches in China from which the company expects to derive substantial revenue. On December 11, 2023, the company established a wholly-owned subsidiary, Gilmore Inv, to focus on kinesiology and recreation, and on January 18, established a subsidiary, SouthGilmore, 40% owned by the company, to organize sports entertainment projects, many of which it anticipates will be large-scale in nature. These new entities represent a new strategic direction for the company which it expects to further diversify its revenue stream and lead to higher corporate growth.

08:35 EST Bridgeline Digital's HawkSearch implemented by Saviynt - Bridgeline Digital announced the launch of HawkSearch within Saviynt's customer support portal. Saviynt, a leader in cloud identity and access governance, has integrated HawkSearch to improve its internal site search capabilities. HawkSearch will bolster Saviynt's growth strategy with its AI-powered search, designed to offer a more personalized user experience. The integration includes a custom connector and a federated search model, enabling HawkSearch to index data from several third-party sources. Ari Kahn, CEO of Bridgeline Digital, commented on the achievement: "Our partnership with Saviynt demonstrates our ability to adapt and deliver solutions in an evolving landscape. The launch of HawkSearch within Saviynt's support portal enhances their capabilities and underscores the effectiveness of our search technology in meeting diverse client needs."

08:35 EST Peloton CEO: Tread an 'important second leg of the stool'

08:34 EST Runway Growth Finance board declares supplemental dividend of 7c per share - Runway Growth Finance announced that its Board of Directors has declared a first quarter 2024 regular cash distribution of $0.40 per share. In addition, the Board of Directors declared a supplemental dividend of $0.07 per share, for the first quarter of 2024.

08:32 EST Alcoa to supply Nexans with aluminum - Alcoa announced that it will supply global cable producer Nexans with aluminum produced from a process that eliminates all direct greenhouse gas emissions from the traditional smelting process.

08:32 EST CME Group to launch E-mini S&P 500 Equal Weight futures on February 26 - CME Group announced it will launch E-mini S&P 500 Equal Weight futures on February 26, pending regulatory review. While the S&P 500 Index weights companies based on market capitalization, the S&P 500 Equal Weight Index applies equal weight to all constituents in the index. The addition of these new E-mini contracts will give market participants another tool to deploy hedging and investment strategies across a broad range of potential market scenarios.

08:24 EST Penn Entertainment announces founding family behind theScore to step down - Yesterday, Penn Entertainment announced that the founding family behind theScore -- John Levy, Benjie Levy, Aubrey Levy and Noah Levy - will be stepping down from their roles at Penn Interactive, with John departing in mid-February and with Benjie, Aubrey and Noah departing in April. In conjunction with this planned leadership transition, the company is in the final stages of its search for a new head of interactive. "This transition plan comes at a natural inflection point, with the migration to our proprietary technology platform complete, theScore's media and betting business delivering record results, and ESPN BET off to a strong start," said Jay Snowden, CEO and president of Penn Entertainment. "The Levys are a family of successful entrepreneurs and are truly pioneers in the sports media and gaming industry. I am very proud of what we've been able to accomplish with them, including the development of an extremely deep and talented bench at PENN Interactive. With this experienced, best-in-class team firmly in place, we are well prepared for this to be a seamless transition and to continue growing our position as a leader in online gaming and sports media," said Mr. Snowden. Penn acquired Score Media and Gaming in October 2021 and integrated theScore with its Penn Interactive unit under the leadership of Benjie Levy as Head of Interactive with John Levy assuming the role of executive chairman of theScore.

08:20 EST Siyata Mobile enters partnership with Allcan Distributors - Helix Advanced Communications & Infrastructure, Inc., operating as Allcan Distributors, has entered a partnership with Siyata Mobile as it launches ChatterPTT Canada, a nationwide broadband Push to Talk service. The partnership is a result of Allcan Distributors' introduction of ChatterPTT to Canada. ChatterPTT is a comprehensive business communication service that allows instant connection between remote teams. Hosted in Canada and offered exclusively by Allcan Distributors, ChatterPTT offers nationwide, secure, instant PTT communications services on any IOT broadband network. Allcan Distributors is partnering with Siyata Mobile to provide the hardware and has placed its first stocking order of Siyata's SD7 handset, a simple, functional, and rugged Android-based PTT-only device. The Siyata SD7 is the industry's leading next generation, game changing, cost effective, mission critical PTT over cellular 4G broadband MCPTT Device.

08:17 EST Semper Paratus shareholders approve business combination with Tevogen - Semper Paratus Acquisition Corporation (LGST) announced that its shareholders have approved the proposed business combination with Tevogen Bio Inc, a Delaware corporation, at an extraordinary general meeting of Semper Paratus' shareholders that was held on Wednesday, January 31, 2024. Each of the proposals presented at the Meeting was approved, and the Business Combination is expected to be consummated as soon as practicable following the satisfaction or waiver of the remaining closing conditions described in Semper Paratus' definitive proxy statement, which was filed with the U.S. Securities and Exchange Commission on January 10, 2024, as supplemented by a Supplement No. 1 filed on January 24, 2024 and Supplement No. 1 filed on January 24, 2024, including the condition that the common stock of the combined company will have been approved for listing on a tier of The Nasdaq Stock Market. Following the closing of the Business Combination, common stock of the combined company is expected to begin trading on Nasdaq under the symbol "TVGN".

08:13 EST Integer to showcase recently acquired capabilities at MD&M West - Integer Holdings Corporation will join innovators and industry leaders around the world in exhibiting at MD&M West, Feb. 6-8, 2024, at the Anaheim Convention Center in Anaheim, California. Integer welcomes visitors to booth #1439 to learn more about the company's unwavering commitment to customers as their partner of choice in enhancing the lives of patients through access to Integer's innovative technology, superior quality and dependable manufacturing to accelerate speed to market and reduce development risk. Integer's exhibit will spotlight the recent strategic acquisitions of InNeuroCo and Pulse Technologies, each of which have further enhanced Integer's capability spectrum in the medical device sector. The acquisition of InNeuroCo brings specific expertise in neurovascular solutions and advanced catheter technologies, while the combination with Pulse Technologies enhances capabilities in precision micro machining, backed by proprietary technologies and a focus on high-growth medical markets.

08:12 EST Deutsche Bank to cut 3,500 roles mainly in non-client-facing areas

08:12 EST Sensus Healthcare announces retirement of director O'Rear - Sensus Healthcare announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today.

08:11 EST Aemetis completes construction funding from $25M USDA loan - Aemetis announced the deployment of the entire $25M of funding provided under the previously announced USDA-guaranteed loan for its Aemetis Biogas 1 project company. In addition to the USDA-guaranteed funding, Aemetis Biogas invested $30 million of project equity and has obtained $23 million of grants to date. "Aemetis Biogas is actively growing by constructing additional digesters with a goal of operating digesters supplied by 18 dairies by the end of 2024," stated Eric McAfee, Chairman and CEO of Aemetis. "The funding received by Aemetis Biogas from the 20-year USDA-guaranteed financings allows us to expand the capture of biomethane at dairies to improve local air quality, reduce the global warming effects of methane emissions, and replace fossil diesel fuel in trucks in California."

08:10 EST Perspective introduces 'pre-targeting' Theranostic Technology Platform - Perspective Therapeutics announced that it has executed an exclusive license agreement with Stony Brook University for the rights to its Cuburbit[7]uril-admantane pre-targeting platform and was awarded the Phase I tranche of a 2.5-year, Fastrack Small Business Innovation Research grant from the National Institutes of Health, NIH, National Cancer Institute in support of Perspective's CB7-Adma host-guest pre-targeting program for the diagnosis and treatment of cancer. "By embracing a strategy that leverages the precision of monoclonal antibodies and the versatility of small molecules, Perspective has the opportunity to expand the therapeutic options available to patients receiving radiation therapy," said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics. The exclusive license with Stony Brook University covers the global intellectual property rights for the CB7-Adma pre-targeting platform.

08:08 EST Windtree Therapeutics renews agreement with Chang Gung University - Windtree Therapeutics announced that it has renewed its partnership with Chang Gung University in Taiwan to further research on SERCA2a, an important target for the Company's cardiovascular portfolio. Windtree personnel from its offices in Taipei, Taiwan will participate in the collaboration. The scientific collaboration includes the Company's lead product candidate istaroxime and the next generation compounds called SERCA2a activators. "We are pleased to utilize this scientific collaboration to further support the characterization of the potential benefits of SERCA2a activation in cardiovascular disease and support the advancement of the next generation assets in our portfolio," said Craig Fraser, Windtree's President and Chief Executive Officer. "This collaboration recently provided preclinical data showing reduction in ischemia-reperfusion induced arrythmias with istaroxime and a pure SERCA2a activator compound." Outside of this scientific collaboration, istaroxime is being studied in the Phase 2 SEISMiC Extension Study in early cardiogenic shock. Study results are expected in mid-2024.

08:07 EST NightHawk's Scorpius BioManufacturing names Joe Payne president, COO - NightHawk Biosciences announced the promotion of Joe Payne to President and COO of its Scorpius BioManufacturing subsidiary. Payne joined Scorpius in 2023 as VP of Quality and Regulatory Affairs. In his role as President and COO, Payne will oversee quality, manufacturing, process sciences, and commercial operations.

08:06 EST EDAP TMS announces completion of enrollment in Phase 3 study of HIFU therapy - EDAP TMS announced that it has completed enrollment in its Phase 3 study, Endo-HIFU-R2, evaluating Focal One High-Intensity Focused Ultrasound, HIFU, therapy for the treatment of deep infiltrating rectal endometriosis. The ongoing Phase 3 study is a comparative, randomized, double blind trial, with the primary objective of evaluating acute pelvic pain levels in 60 patients. Select treated patients are followed three months post-HIFU treatment in comparison to a sham group. The last patient was treated in January. Study results are expected in the second half of 2024. "We are pleased to announce the completion of enrollment in our Phase 3 study, which represents a significant clinical milestone for our company," said Ryan Rhodes, Chief Executive Officer of EDAP TMS. "Considering the fact that the Phase 3 study included a sham-controlled arm, we are highly encouraged by the robust pace of enrollment which we believe speaks to the strong interest from patients and physicians in exploring alternative treatment modalities beyond surgery. Rectal endometriosis is a painful and debilitating condition that impacts thousands of women each year with surgical intervention being the primary option beside medical treatment. By utilizing robotic HIFU, we hope to address this significant unmet need in women's health by developing a safe and effective treatment option that is significantly less invasive than conventional surgical approaches. We would like to thank the patients and clinical investigators who participated in this study, and we look forward to reporting results from the study later this year."

08:06 EST Ageagle Aerial Systems attends UMEX 2024 to showcase drones - AgEagle Aerial Systems announced the Company recently attended the UMEX 2024 Unmanned System Exhibition and Conference January 23-24, 2024 together with FEDS Drone-powered Solutions, a leading drone services and value-added distributor of AgEagle's high performance unmanned aerial systems. AgEagle interim CEO, Grant Begley, commented, "Opportunities to educate the public safety and security market on the unique value propositions of AgEagle's leading edge UAS solutions are invaluable. Attending UMEX 2024 alongside FEDS, our trusted partner and customer, denotes a key milestone in the advancement of our growth strategy as their recent purchase of the eBee VISION marks our first sale in the Middle East, opening a robust new market for our drone systems. We will continue to leverage significant industry events to forge new relationships with potential customers and strategic counterparts as part of our commitment to building long-term shareholder value."

08:05 EST Golden Heaven announces trial operation of Seven Rainbow Park - Golden Heaven announced the trial operation of Seven Rainbow Park in Anshun City, Guizhou Province. The construction of the Park was completed ahead of schedule and the company commenced the trial operation of the Park in January 2024. The company expects the Park to provide entertainment for guests, especially during the winter holiday and the Chinese New Year. An estimated total of RMB140M is expected to be invested in the Park, of which amount, approximately RMB41M has already been invested in the Park to date.

08:03 EST Etsy appoints Marc Steinberg to its Board of Directors - Etsy has appointed Marc Steinberg, Partner at Elliott Investment Management, to the company's Board, effective February 5, 2024. He will also join the Board's Audit Committee. At Elliott, Steinberg is responsible for public and private equity investments across a range of industries. He currently serves on the boards of directors of Pinterest as well as three private companies: Nielsen Holdings, plc, a global company in audience insights, data, and analytics; Syneos Health, a fully integrated biopharmaceutical solutions organization; and Cubic, a technology-driven provider of solutions for public transit and defense applications. Previously, Steinberg served as a director of Athenahealth, a private provider of network-enabled services focused on the healthcare sector. Prior to joining Elliott in 2015, Steinberg worked at investment bank Centerview Partners.

07:57 EST Udemy announces generative AI roadmap for skills development - Udemy announced a series of generative AI-enabled offerings designed to support personalized learning and enhanced skills development. The comprehensive Udemy Intelligent Skills Platform will include Udemy AI Learning Assistant, Udemy AI Skills Mapping and several new enhancements for content creators/instructors, such as a gen AI-assisted Q&A feature. Scheduled to launch throughout 2024, the Udemy gen AI-powered ecosystem will empower organizations with personalized learning solutions for professionals by facilitating the discovery, development and validation of competitive skills crucial to accomplishing business objectives. Udemy's AI-oriented offerings, as well as its overall Intelligent Skills Platform, will support employee training and development, enabling faster real-world application of new skills and integrating learning into existing workflows.

07:38 EST Laser Photonics receives order from Liberty Utilities for MarkStar Pro system - Laser Photonics Corporation (LASE) received an order from Liberty Utilities, an Algonquin Power & Utilities Corp. (AQN) subsidiary, for its MarkStar 20-MSH-Pro laser marking system.

07:36 EST Revive Therapeutics explores use of bucillamine for long COVID - Revive Therapeutics announced its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company aims to advance the clinical development of Bucillamine by leveraging the published research and existing data from its previous Phase 3 clinical trial and is preparing a clinical package that includes a proposed Phase 2/3 clinical protocol for long COVID to present to the FDA and international health regulatory bodies. On July 6, 2023, the Company announced the results of its Study evaluating the safety and efficacy of oral Bucillamine in patients with mild to moderate COVID-19. Under the Study's primary endpoint, the proportion of patients meeting a composite endpoint of hospitalization or death from time of first dose through Day 28 following randomization, there were no deaths and four hospitalizations, of which three were from the placebo arm and one from the Bucillamine low dose group. No hospitalizations occurred in the Bucillamine large dose group. The Company also evaluated certain Study endpoints, including the COVID-19 clinical symptoms data. Based on preliminary analyses, the data demonstrated that for patients with oxygen saturation less than96% at baseline, Bucillamine had a 29.1% improvement over placebo in time to normal oxygen saturation. A study titled "Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry" showed that thiol-based drugs, like Bucillamine, decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. These findings uncovered a vulnerability of SARS-CoV-2 to thiol-based drugs and provided a rationale to test thiol-based drugs such as Bucillamine as a novel treatment for COVID-19.

07:34 EST Purple Biotech reaches recommended Phase 2 dose for NT219 - Purple Biotech has determined 100mg/kg is the recommended Phase 2 dose for NT219 in combination with cetuximab in the treatment of head and neck cancer based on its Phase 1/2 dose escalation study. NT219 is a first-in-class small molecule dual inhibitor of IRS1/2 and STAT3. The RP2D was determined based on data from the open-label dose escalation study designed to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of NT219 in combination with Erbitux, in previously treated recurrent and/or metastatic squamous cell carcinoma of the head and neck patients. The Company recently reported that NT219, in combination with cetuximab, demonstrated a dose dependent anti-tumor activity with confirmed partial responses. No dose-limiting toxicities were reported. The additional supporting data used for this determination was pharmacokinetics of NT219 across all dose levels. Further dose optimization is planned for future studies. The Phase 1 dose escalation study is being concluded and the remaining patients' data are expected to be reported during the first half of 2024. The Company is now advancing its upcoming Phase 2 Proof of Concept study of NT219 for the treatment of R/M SCCHN. Detailed clinical results from the dose escalation portion of the study are intended to be presented at the European Society of Medical Oncology Targeted Anticancer Therapies Congress 2024 in Paris on February 26, 2024, in an Oral Presentation titled "Interim results of a Phase 1/2 trial of NT219 in combination with cetuximab in patients with advanced/metastatic Squamous Cell Carcinoma of the Head and Neck."

07:32 EST BioRestorative Therapies to present preliminary BRTX-100 data at ORS meeting - BioRestorative Therapies announced that preliminary 26-52 week blinded data from the ongoing Phase 2 clinical trial of BRTX-100 in subjects with chronic lumbar disc disease will be presented by Francisco Silva, Vice President of Research and Development, at the Orthopaedic Research Society 2024 Annual Meeting, taking place February 2-6, 2024 in Long Beach, California. BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, is the Company's lead clinical candidate. The safety and efficacy of BRTX-100 in treating cLDD is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study. A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States. Subjects included in the trial will be randomized 2:1 to receive either BRTX-100 or placebo. The presentation, titled "Autologous Stem Cell Therapy for Chronic Lumbar Disc Disease, Initial Phase 2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells," is scheduled for Sunday, February 4, 2024 between 10:15am-11:15am PST.

07:29 EST Treace to show product innovations, ALIGN3D study outcomes at ACFAS conference - Treace Medical Concepts will highlight new technology innovations and three-year interim ALIGN3D clinical results at the 2024 American College of Foot and Ankle Surgeons Annual Scientific Conference in Tampa, Florida from February 1-4, 2024. Treace will feature its current and next-generation technologies at its ACFAS exhibit booth and host Lapiplasty and Adductoplasty surgeon training events featuring recent innovations.

07:24 EST Allegion acquires UK-based Boss Door Controls, terms undisclosed - Allegion has acquired, through one of its wholly owned subsidiaries, Boss Door Controls. Established in 2009 and based in Livingston, Scotland, Boss Door Controls is a door solutions provider in the UK. Serving customers in the specified door hardware market, its portfolio includes door closers and levers, automatic door operators and pocket door frames. Boss Door Controls will operate as part of the Allegion International segment, led by Allegion Senior Vice President Tim Eckersley. "Bringing Boss Door Controls to Allegion both complements and expands how we go to market in the UK, bolstering our local business with a strong architectural channel and a flexible supply chain," Eckersley said. "Most importantly, Boss Door Controls has a reputation of being a customer-centric company, which aligns to Allegion's position as a leading partner of choice in our industry. Together, we'll offer our customers a larger network of door hardware specification experts and a broader portfolio of products and solutions that can be tailored to meet their unique needs." ...Terms of the transaction were not disclosed.

07:23 EST Societal CDMO, Benuvia sign co-marketing agreement to promote CDMO, API - Societal CDMO and Benuvia Operations announced the signing of a co-marketing agreement. The agreement is designed to allow the companies to promote each other's complementary contract development and manufacturing services to their respective customer bases and new business prospects. As part of the agreement, the companies will highlight Benuvia's specific expertise as a manufacturer of drug substance, API, and Societal's focus on manufacturing drug product. While the agreement is not limited to any specific therapeutic indication or modality, the companies will specifically focus on leveraging their unique expertise in the area of psychedelics to address this expanding drug development market. "We are excited about the strategic alignment offered by our new relationship with the Benuvia team. Our respective services and capabilities are completely complementary with little to no overlap. This allows us to aggressively promote and advocate for each other in the exciting and rapidly growing psychedelic drug development market," said Scott Rizzo, senior vice president and chief operating officer of Societal CDMO.

07:20 EST Peloton CEO says biggest challenge continues to be growth at scale - CEO Barry McCarthy said in a shareholder letter, "For the second consecutive year we reported strong Q2 results, outperforming on paid subscribers to Connected Fitness and App, gross margin and free cash flow. Q2 is our most important quarter of the year from a sales standpoint. On the road to recovery, good performance every quarter matters, but Q2 matters most of all. Our guidance for the remainder of FY24 represents our current best thinking about the future performance for the business, but I'll be disappointed if we can't figure out how to improve our performance during the quarter, like we did in Q2. While we continue to outperform the connected fitness market, our biggest challenge continues to be growth, at scale. Those of you who have followed the business know we've launched a number of new growth initiatives over the last two years. Overall I'm extremely pleased with the new muscles we have developed in this regard. We'll strengthen these muscles as we continue to explore ways to ignite growth across multiple vectors. Several of these new initiatives have performed strongly. Some have not. We review both in this quarterly update, beginning with the failures. If we're not failing, we're not being aggressive enough testing new initiatives. One initiative that hasn't worked is our premium co-branded Bike experiment with the University of Michigan. Notwithstanding the football team's success winning the national championship, we sold substantially fewer Bikes to alumni and boosters than we expected. What seemed like a good idea didn't deliver. So instead of launching additional co-branded bikes in school colors, we will end-of-life this hardware initiative. Another area of the business which failed to meet our performance expectations was Member Support. This past holiday season was particularly taxing for Members. The Member Support experience has tarnished our brand, and we simply must do better. The team is currently in the middle of a reboot. New leadership. New systems. New third party vendors. New training. New staff. I'm confident we're on the right path this time. I'm confident in the new leadership, and I'm confident that in the next few months our Members will be receiving the level of service they deserve and expect and that we can be proud of...When I first joined Peloton, I spoke publicly about two primary goals for the business: stop the bleeding and return the business to growth. My primary goal for FY24 has been to restore the company to positive free cash flow for the full year. Based on our updated forecast, we now expect the business to generate positive free cash flow in Q4 but to fall short of achieving our goal for the full year. We also expect to end the fiscal year with a net increase in unrestricted cash compared to our Q2 balance. If we grow our cash balance and generate free cash flow, we will have stopped the bleeding. As for the goal of restoring revenue growth, we expect to meet that goal in 4Q24."

07:19 EST Natural Gas Services appoints Justin Jacobs as Chief Executive Officer - Natural Gas Services Group announced the appointment of Justin Jacobs as Chief Executive Officer of NGS, effective February 12, 2024. The appointment concludes an extensive and thorough search process undertaken by the Board of Directors over the past year. Stephen Taylor, who serves as Interim Chief Executive Officer, will remain Chairman of Board of NGS and will provide transition services for 6 months as per his retirement agreement. Jacobs joins NGS from Mill Road Capital, an investment firm focused on investing in, and partnering with, small publicly traded companies in the U.S. and Canada.

07:15 EST Bitfarms produces 357 bitcoin in January - Bitfarms provides an update for the month ended January 31, 2024. January production of 357 BTC represented a decrease of 20.0% from December as powerful winter storms across North America drove significantly higher energy curtailment, which is part of the grid stability programs in Quebec, and offsetting a network difficulty decrease of 2.3% during January. "In 2024, we are embarking on an aggressive growth plan, targeting hashrates of 12 EH/s in 1H 2024 and 21 EH/s in 2H 2024," said Geoff Morphy, President and Chief Executive Officer of Bitfarms. "The new farm development in Paraguay is expected to drive much of this growth. With land purchased for our 100 MW facility in Yguazu and shipment of the main transformer for Paso Pe, our expansion projects continued on schedule in January. This transformative fleet upgrade and growth plan are being undertaken to position Bitfarms to gain market share and be among the lowest cost producers during this Halving year, which is anticipated to be an inflection point for the industry."

07:14 EST Ceridian announces legal name change, brand to Dayforce - Dayforce announced its change in legal name and brand from Ceridian to Dayforce. Dayforce is the Company's flagship HCM platform, which delivers value to thousands of organizations and millions of workers globally and has consistently been ranked as a market leader based on a rich history of innovation and excellence. "As one united brand - Dayforce - we firmly believe we can amplify our promise to make work life better," said David Ossip, Chair and CEO, Dayforce, Inc. "Dayforce represents our products, company, and community at its best. As Dayforce, we will further our ability to foster the happiest customers, the most engaged employees, the best products, and the greatest return for the market."

07:12 EST Plug Power completes customer fill of liquid green hydrogen at Georgia plant - Plug Power has completed the first fill of a Plug tanker with liquid green hydrogen produced at its Woodbine, Georgia production plant, heading straight off to customer sites. The achievement comes one week following the official commencement of operations at the plant. A Plug cryogenic trailer has been filled with liquid hydrogen for use at Walmart, Amazon and Home Depot sites. This is enough liquid hydrogen to fuel 3,216 forklifts a day. Plug's Georgia plant currently operates eight 5-megawatt electrolyzers, the largest proton exchange membrane electrolyzer deployment in the U.S. "The first delivery of our green hydrogen molecule marks a critical milestone for the green hydrogen economy," said Andy Marsh, CEO of Plug. "If you want to see the hydrogen ecosystem of the future, it's at Plug today. There's no doubt that Plug is demonstrating the future with real products and projects at scale."

07:10 EST Peloton reports Q2 members down 4% y/y at 6.4M - Reports Q2 subscription churn of 1.2% vs. 1.2% in 2Q23. The company said, "We ended the quarter with 3.00 million Ending Paid Connected Fitness Subscriptions, reflecting a net increase of 40 thousand in the quarter. Average Net Monthly Paid Connected Fitness subscription churn was 1.2%, outperforming internal expectations. Our churn result was positively impacted by fewer than anticipated new subscription pause requests as well as faster than anticipated reactivation rates for subscription pauses associated with our seat-post recall. Gross additions were also positively impacted by faster than anticipated hardware delivery times and continued growth in CF subscriptions associated with secondary market sales. Paid App Subscriptions We ended the quarter with 718 thousand Peloton App subscribers, reflecting a net reduction of 44 thousand in the quarter. Paid App Subscriptions exceeded our forecast due to slightly higher than expected additions coupled with lower than expected Average Monthly Paid App Subscription churn of 7.2%. Our premium tier App+ subscription additions continue to track ahead of expectations."

07:08 EST Kirby announces Chairman Pyne to retire, Alario to succeed - The company announces the retirement of Joseph Pyne, Kirby's Chairman of the Board who will not stand for reelection upon the expiration of his current term, which expires at the conclusion of Kirby's 2024 Annual Stockholders meeting on April 26, 2024. Pyne has served as Chairman of Kirby since April 2010 and has been a board member for 35 years. Succeeding Pyne is Richard "Dick" Alario who has been elected as Chairman of the Board, effective April 26, 2024. Alario has been a board member since 2011.

07:07 EST Kirby expects businesses to deliver 30%-40% earnings growth in 2024 - Commenting on the 2024 full year outlook, David Grzebinski, Kirby's President, and Chief Executive Officer, said, "We ended 2023 in a position of strength in both of our segments. In marine transportation, barge utilization and customer demand remain strong, and rates continue to increase. In distribution and services, demand for our products and services remains strong, and we continue to receive new orders in manufacturing. Overall, we anticipate our businesses to deliver 30% to 40% earnings growth in 2024. Key risks putting us at the lower end of this range or below would be the impact from a recession or lingering inflation. Achieving the higher end of this range would be driven by stronger than expected chemical markets for marine and stronger than expected oil and gas markets for distribution and services."

06:47 EST Macau reports January casino revenue up 67% to 19.34B patacas - Macau's gaming bureau reported January gross revenue from games of fortune in the region was up 67.0% year-over-year to 19.337B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link

06:42 EST Merck reports Q4 Keytruda sales $6.6B, up 21% y/y - Up 22% ex-FX.

06:35 EST Merck says Harpoon acquisition included in FY24 guidance - In early January 2024, Merck announced the acquisition of Harpoon, which is expected to close in the first half of 2024, and result in a non-tax deductible charge of approximately $650M of R&D expense included in non-GAAP results. The impact of the transaction on expected full-year non-GAAP EPS is approximately 26c per share, which is included in the 2024 outlook.

06:18 EST GSK confirms confidential Zantac settlement reached with David Browne - GSK plc confirmed it has reached a confidential settlement with David Browne, resolving the case he filed in California state court. This case was set to go to trial on February 20, and instead will now be dismissed. "The settlement reflects the Company's desire to avoid the distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases," the company stated.

06:14 EST Brenmiller Energy signs agreement for seven-year, $3.55M project in Israel - Brenmiller Energy announced it has signed a definitive agreement for a seven-year, $3.55M project to supply electric process heat to Wolfson Hospital, a public medical center located near Tel Aviv in Holon, Israel. The Israeli Ministry of Finance approved a budget of up to $3.55M for Wolfson Hospital to procure a bGen ZERO system from Brenmiller, from which Brenmiller will generate recurring revenues on an energy-as-a-service model from the supply of electric process heat over the course of the seven-year project. As previously announced by the Company, a grant of up to $450,000 from the Israel Innovation Authority will cover part of the budget. bGen ZERO will replace Wolfson Hospital's old diesel boilers that are both costly and polluting. According to the Israeli Ministry of Finance's estimates, electric heat provided via Brenmiller's bGen ZERO TES system has the potential to save Wolfson Hospital up to $1.3M annually and reduce the hospital's local carbon footprint by 3,900 tons per year.

06:06 EST Deutsche Bank announces EUR 1.6B of proposed capital distributions - The bank plans to recommend 2023 dividends of EUR 900 million, or EUR 0.45 per share, up from EUR 0.30 per share for 2022, at its Annual General Meeting in May 2024. Having raised its capital outlook by EUR 3 billion in October 2023, the bank is well positioned to exceed its capital distribution goal of EUR 8 billion in respect of the financial years 2021-25, paid in 2022-26. The bank also published updated guidance for a proposed dividend of EUR 1.00 per share for the financial year 2025, subject to delivery of financial targets and to a 50% payout ratio.

05:59 EST Genentech announces new 72-week data from BALATON, COMINO studies - Genentech, a member of Roche, announced new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo in macular edema due to branch and central retinal vein occlusion, or BRVO and CRVO. Whereas available RVO treatments are typically given every one to two months, the data showed nearly 60% of people receiving Vabysmo in BALATON and up to 48% of people in COMINO were able to extend their treatment intervals to three or four months apart. In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year. Retinal drying is an important clinical measure as swelling from excess fluid in the back of the eye has been associated with distorted and blurred vision. In both studies, Vabysmo was well tolerated and the safety profile was consistent with previous studies. Both studies evaluated the average change in best-corrected visual acuity, or BCVA, score from baseline. The studies also tracked the amount of swelling in the back of the eye due to retinal fluid, as measured by central subfield thickness, or CST. Reductions in CST indicate improvement. Overall, results showed the vision improvements and reductions in retinal fluid achieved in the first 24 weeks of the studies were maintained up to 72 weeks. At 72 weeks, people receiving Vabysmo as a first-line treatment gained 18.1 letters on the eye chart, while people switched from aflibercept to Vabysmo gained 18.8 letters. During the first 24 weeks, vision gains were +16.8 eye chart letters in people receiving Vabysmo and +17.5 letters in people receiving aflibercept. Retinal drying: At 72 weeks, people receiving Vabysmo as a first-line treatment saw a 310.9 microm reduction in retinal swelling, as measured by CST, while those switched from aflibercept to Vabysmo saw a reduction in CST of 307 microm. During the first 24 weeks of the study, CST reductions were 314.5 microm in people receiving Vabysmo and 307.6 microm in people receiving aflibercept. People receiving Vabysmo as a first-line treatment gained 16.9 eye chart letters at 72 weeks, while people switched from aflibercept to Vabysmo gained 17.1 eye chart letters. During the first 24 weeks of the study, vision gains were +16.9 eye chart letters in people receiving Vabysmo and +17.3 letters in people receiving aflibercept. Retinal drying: People receiving Vabysmo as a first-line treatment saw a 465.9 microm reduction in retinal swelling, as measured by CST, while those switched from aflibercept to Vabysmo saw a reduction in CST of 460.6 microm at 72 weeks. During the first 24 weeks of the study, reductions in CST were 462.3 microm in people receiving Vabysmo and 447.8 microm in people receiving aflibercept.

05:55 EST Volvo expects rise in investment levels going forward - The company said, "Volvo Cars is now entering a decisive phase in its transformation journey. Not only will it continue to roll out and ramp up production of the EX30, EX90 and EM90 in 2024, but the company is also significantly ramping up other investments that will help it become a leader in next-generation mobility. In the period up until 2025 Volvo Cars will make the necessary structural and strategic investments that lay the technical foundation for its future success: electrification, software, core computing architectures, advanced connectivity, data capture and analytics, mega casting, next generation e-motor and battery technology, smart cabin technology, and a new advanced manufacturing facility. This will mean a temporary rise in investment levels, yet these strategically crucial investments will drive significant cost efficiencies in Volvo Cars' next generation of fully electric cars. They lay the foundation for further profitable growth and increased EV margins. The company has a strong balance sheet supporting the transformative investments, with a liquidity position of SEK 75 bn as of year-end 2023, and during the investment phase in 2024-25 it expects the free cash flow generation to be relatively neutral. From 2026 and onwards, Volvo Cars not only expects the level of investments to decline but to reap the benefits of this strategy with higher growth and profitability. It will also at this point generate a strong positive free cash flow. As the company accelerates its transformation, it will put even more emphasis on driving profitable growth over time and prioritising value over volume. It will double down on internal efficiency, ensure robust capital allocation across our business and capitalise on its phase one investments."

05:37 EST Shell to increase dividend by 4% - The company said, "Shell delivered another quarter of strong performance, concluding a year in which we made good progress across the targets outlined at our Capital Markets Day1. As we enter 2024 we are continuing to simplify our organisation with a focus on delivering more value with less emissions. In 2023, Shell returned $23 billion to shareholders. In line with our progressive dividend policy, Shell is now increasing its dividend by 4%. We are also commencing a $3.5 billion buyback programme for the next three months."

05:30 EST Shell commences $3.5B share buyback program - Shell announced the commencement of a $3.5B share buyback program covering an aggregate contract term of approximately three months. The purpose of the program is to reduce the issued share capital of the company. All shares repurchased as part of the program will be cancelled. It is intended that, subject to market conditions, the program will be completed prior to the company's Q1 results announcement, scheduled for May 2. The company has entered into an arrangement with a single broker consisting of three irrevocable, non-discretionary contracts, to enable the purchase of ordinary shares on both London market exchanges and Netherlands exchanges for a period up to and including April 26, 2024. The aggregate maximum consideration for the purchase of ordinary shares under the London contracts is $2B and the maximum consideration for the purchase of ordinary shares under the Netherlands contract is $1.5B. The maximum number of ordinary shares which may be purchased or committed to be purchased by the company under the program is 480M, which is the maximum number remaining as of the date of this announcement pursuant to the relevant authorities granted by shareholders at the company's 2023 annual general meeting.

05:20 EST XPeng delivers 8,250 Smart EVs in January - XPeng announced its vehicle delivery results for January. In January, XPeng recorded monthly deliveries of 8,250 Smart EVs, representing a 58% increase year-over-year. In early January, the company launched its X9 Ultra Smart Large Seven-seater MPV, followed by immediate deliveries across more than 100 cities in China. In January, 2,478 X9s were delivered and orders for X9 Max trim accounted for approximately 70% of total X9 orders. The X9 has showcased its outstanding product competitiveness and cutting-edge smart technology, catering for needs of families. The company is currently ramping up its production capacity for the X9 and accelerating the delivery for customers. The company aims to extend its end-to-end XNGP coverage to major urban road networks, parking spaces, and private roads nationwide by 2024. Additionally, XPeng plans to initiate R&D on Highway NGP for overseas markets this year and on XNGP in 2025.

05:13 EST Nio delivers 10,055 vehicles in January, up 18.2% - Nio announced its January delivery results. Nio delivered 10,055 vehicles in January, increasing by 18.2% year-over-year. The deliveries consisted of 6,307 premium smart electric SUVs, and 3,748 premium smart electric sedans. Cumulative deliveries of Nio vehicles reached 459,649 as of January 31. Nio has opened up its power swap network to the entire industry. In January, Nio signed strategic partnership agreements with JAC Group and Chery Automobile on battery swapping, following the previously announced cooperation with Changan Automoile and Geely Group. Additionally, Nio, along with other investors, jointly established Zhongan Energy, a company dedicated to advancing the establishment of an open and shared charging, swapping and energy storage network, in January 2024. Zhongan Energy targets to build 1,000 battery swap stations in China in the upcoming years. Moving forward, Nio expects to join hands with more partners to collectively contribute towards the development of power network and the wider adoption of battery swapping.